Latest Breaking News On - Peggy peck - Page 3 : comparemela.com
Latest SYNTAX Score Validated in Real World Study
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
ESC: Analysis of Pooled Data Finds No Renal Benefit for Empagliflozin in HFpEF
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
Covid-19: Small Case Series Details Myocarditis in Teens Post Vaccination
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
May 27, 2021
Biomarker synthesized by Th17 cells appears to differentiate myocarditis from MI
Differentiating acute myocarditis from myocardial infarction (MI) requires either an invasive biopsy or cardiac MRI technology that is not always available so the possibility that a microRNA biomarker in circulating T cells could be used to confirm myocarditis is appealing.
Identifying that novel miRNA was the goal of Rafael Blanco-Dominguez, MSc, of the Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares in Madrid, and a team of international researchers, who started by inducing autoimmune myocarditis or myocardial infarction in mice to identify the microRNA found in Th17 cells in plasma of mice with acute myocarditis either autoimmune or virus-induced.
May 19, 2021
Current guidelines strongly recommend use of the therapy for cardiology, diabetes patients
In a series of presentations at ACC.21, the virtual meeting of the American College of Cardiology, researchers delivered data to confirm two observations about cardiovascular outcomes in heart failure patients with or without type 2 diabetes (T2D) and/or chronic kidney disease (CDK). First, the use of SGLT2 inhibitors is associated with reduced risk of cardiovascular death, worsening heart failure, and/or hospitalization for heart failure, and second, SGLT2i agents are woefully underused.
In a presentation titled, “Just Go With the Flo(zin): SGLT2i Should Be Added to A Few, Some, Most, All HFrEF Patients?”, Glenn Herrington, PharmD, Ambulatory Care Cardiology Pharmacist at New Hanover Regional Medical Center in Wilmington, North Carolina, reviewed findings from EMPA-REG OUTCOME, CANVAS PROGRAM,DECLARE-TIMI 58, VERTIS CV, DAPA-HF, and EMPEROR-REDUCED to assess benefits and